22
Views
26
CrossRef citations to date
0
Altmetric
Original Article

Neomycin Concentrations in Inner Ear Tissues and Other Organs of the Guinea Pig After Chronic Drug Administration

&
Pages 233-236 | Received 18 Mar 1981, Published online: 08 Jul 2009
 

Abstract

The kinetics of neomycin entry into tissues, including those of the inner ear, was studied in the guinea pig. The animals received daily subcutaneous injections of 100 mg neomycin/kg body weight and were killed after I, 3, and 6 days and 1, 2, and 3 weeks. In agreement with previous studies, kidney accumulated the drug rapidly and to a high level (450 mu.g neomycin/g tissue at day 7) while levels in heart, liver, lung, and spleen were lower by more than one order of magnitude. The drug was virtually absent from brain at all times. The salient finding was that neomycin content of cochlear tissues was relatively low. For instance, at 2 weeks, concentrations in organ of Corti (0.7 mug/mg protein) and lateral wall tissues (0.4 mug) were similar to those in heart (0.3 mug), liver (0.5 mug), lung (0.8 mug) and spleen (0.6 mug) while the concentration in kidney was 6.8 mu.g neomycin/mg protein. The results show that mechanisms of drug entry are different for kidney and cochlea. They also show that the frequently discussed‘accumulation’of aminoglycosides in perilymph is apparently not reflected in tissue levels of the drug.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.